Carl Zeiss Meditec achieves further significant growth in revenue and order intake in first half 2021/22

Strained supply chain situation in equipment business continues

Jena, Germany | 13 May 2022 | Carl Zeiss Meditec AG

 

Carl Zeiss Meditec generated revenue of €855.4m in the first six months of fiscal year 2021/22 (prior year: €767.4m), corresponding to an increase of 11.5% (adjusted for currency effects: +10.7%) compared with the same period of the prior year. Order intake rose to an even greater extent than revenue, climbing 30.7% to €1,062.3m (prior year: €812.9m). Earnings before interest and taxes (EBIT) increased slightly to €177.3m. The EBIT margin was 20.7% (prior year: 21.2%). The adjusted EBIT margin amounted to 21.2% (prior year: 21.4%), which approximates the previous year’s figure.

Dr. Markus Weber: “The supply chain situation in the equipment business has deteriorated further in the past few months – due, among other things, to the war in Ukraine and the COVID-19 lockdowns in China. I am therefore all the more delighted to be reporting these good half-year results – an outstanding team achievement.”

Contributions to growth from all strategic business units and regions

Revenue in the strategic business unit (SBU) Ophthalmic Devices increased by 10.5% in the first six months of fiscal year 2021/22 (adjusted for currency effects: +9.7%) to €651.9m (prior year: €590.1m). Recurring revenue from consumables, implants and services once again contributed significantly to growth. The equipment business is impacted by supply chain bottlenecks. Order intake in the Ophthalmic Devices SBU increased disproportionately to revenue. Revenue in the Microsurgery SBU increased by 14.8% (adjusted for currency effects: +13.8%) to €203.5m (prior year: €177.3m). Order intake in the Microsurgery SBU likewise increased at a much higher rate than revenue.

Revenue in the EMEA1 region increased by 5.8% (adjusted for currency effects: +7.1%) to €229.2m (prior year: €216.7m). Order intake in core European markets exhibited a positive trend.

Revenue in the Americas region increased by 7.6% (adjusted for currency effects: +2.6%) to €212.2m (prior year: €197.2m). Contributors to this are both the stable development in the USA as well as a further recovery in the countries of South America.

In the APAC2 region, revenue increased to €414.1m, compared with €353.5m in the prior year (+17.1%; adjusted for currency effects: +17.3%). The strongest contributions to growth came from China and India. The Japanese market also recorded growth.

EBIT margin only slightly below prior-year level in spite of planned higher investments

The operating result (earnings before interest and taxes: EBIT) increased to €177.3m in the first six months of fiscal year 2021/22 (prior year: €162.7m). The growth in revenue with a solid share of recurring revenue had a positive effect on this. Planned larger investments in Sales & Marketing and Research & Development had a curbing effect. EBIT in the prior year also included positive extraordinary income of €2.4m from the sale of a property. The EBIT margin decreased slightly to 20.7% (previous year: 21.2%). Adjusted for special effects, this amounted to 21.2% (prior year. 21.4%) approximating the previous year’s figure. Earnings per share increased to €1.44 (prior year: €1.12).

The Company’s outlook for fiscal year 2021/22 remains unchanged: Revenue is expected to grow at least to the same extent as the market. One factor of uncertainty is posed by the continued strain in the global supply chains, particularly in the equipment business. Political and macroeconomic factors such as the war in Ukraine and the regional COVID-19 lockdowns in China are contributing to this. The risks of supply disruptions increased significantly; further bottlenecks are expected in the present third quarter. The EBIT margin is expected to range between 19-21% in fiscal year 2021/22.

These projections are based on the assumption that there will continue to be no material loss of revenue due to disruptions to the supply chains and that the COVID-19 situation in China will normalize in the third quarter of 2021/22.

Revenue by strategic business unit

All figures in €m

6 months
2021/22

6 months
2020/21

Change from
previous year 

Change from
prior year
(currency-adjusted)

Ophthalmic Devices

651.9

590.1

+10.5%

+9.7 %

Microsurgery

203.5

177.3

+14.8 %

+13.8 %

Overall group

855.4

767.4

+11.5 %

+10.7 %

Revenue by region

All figures in €m

6 Months
2021/22

6 Months
2020/21

Change from
previous year

Change from
prior year
(currency-adjusted)

EMEA

229.2

216.7

+5.8 %

+7.1 %

Americas

212.2

197.2

+7.6 %

+2.6 %

APAC

414.1

353.5

+17.1 %

+17.3 %

Overall group

855.4

767.4

+11.5 %

+10.7 %

Further information on our publication and the Analyst Conference Call on the results for the first six months of fiscal year 2021/22 can be found at
https://www.zeiss.com/meditec-ag/investor-relations/financial-calendar/conference-calls.html

Press Contact

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com

Brief Profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,531 employees worldwide, the Group generated revenue of €1,646.8m in fiscal year 2020/21 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med

Press Contact

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com

Share
Further Articles

Change to the Management Board of Carl Zeiss Meditec AG

Management Board member Jan Willem de Cler to leave the Company at his own request and on good terms.

8 Sep 2022

ZEISS Integrated Workflow Solutions are Creating the Digital Transformation in Healthcare

The fully connected environment, digital technologies and artificial intelligence tools enable optimization of patien...

30 Aug 2022

Carl Zeiss Meditec achieves further significant growth in revenue and order intake after nine months of 2021/22

5 Aug 2022